Reify Health, which makes cloud-based tools for clinical trial research, raises $30M Series B led by Battery Ventures, bringing total raised to almost $40M
Christine Hall / Crunchbase News :
Context & Ripple Effects
This August 2020 round now reads as the entry point to one of the steepest repricing curves in health tech. Reify Health went from almost $40M in total funding here to a $220M Series C at a $2.2B valuation a year later, then a $220M Series D co-led by Altimeter and Coatue at $4.8B-plus by April 2022 — a hundredfold-plus jump in headline valuation inside roughly twenty months.
The raise also landed at the start of a broader funding wave in clinical-trial software: Evidation Health had just pulled in a $45M Series D for virtual-trial data aggregation, and over the following two years Medable, Castor, and Curebase all raised at escalating sizes, with hedge funds and growth giants joining the cap tables.
First-order effects
- Battery Ventures converts a $30M lead check into an early position in what became a multi-billion-dollar franchise, while Reify gains the runway to scale its cloud-based trial tooling ahead of the 2021–2022 mega-rounds.
Second-order effects
- Competitors were forced to raise at matching or larger scale to keep pace — Medable followed with a $304M Series D backed by Blackstone Growth and Tiger Global, while Castor ($45M Series B) and Curebase ($40M Series B) secured mid-stage rounds of their own.
Third-order effects
- If the pattern holds, clinical-trial software consolidates from a fragmented SaaS niche into a capital-intensive category where late-stage funds set the terms, raising the bar for any new entrant without a comparable war chest.
The trend: Cloud-based clinical-trial software repriced faster than almost any health-tech category between 2020 and 2022, with each successive round pulling larger generalist funds into the space.